Key takeaway
Across 7 trials with 709 people, high-frequency rTMS aimed at the left prefrontal cortex improved sleep quality (SMD 0.97) and depressive symptoms (SMD 0.61) compared with controls. Evidence was very low to low certainty, with large heterogeneity for sleep quality (I2 = 91%), so the authors call it exploratory.
Study design
Trial meta-analysis
Reading basis
Published abstract
Reading focus
Design & applicability
The research question
Depression and insomnia often occur together and are hard to treat. The authors pooled randomized trials to test whether high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) of the left dorsolateral prefrontal cortex (DLPFC) helps both.
Who and how
Systematic review and meta-analysis of randomized controlled trials of left DLPFC-targeted HF-rTMS in patients with comorbid depression and insomnia: 7 studies, 709 participants (367 rTMS, 342 control). Treatment effects on sleep and depression were pooled as standardized mean differences (SMD) with 95% confidence intervals, and subgroup analyses explored heterogeneity. The abstract does not report the search databases or dates.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Sleep quality improved with rTMS (SMD 0.97, 95% CI 0.23 to 1.71, p = 0.01), and so did depressive symptoms (SMD 0.61, 95% CI 0.38 to 0.84, p < 0.00001).
- 2Sleep latency showed only a non-significant trend toward reduction (SMD 0.50, 95% CI -0.17 to 1.18, p = 0.14).
- 3Adverse reactions did not differ significantly between groups (risk ratio 1.09, 95% CI 0.80 to 1.48, p = 0.57).
- 4Heterogeneity was substantial for Pittsburgh Sleep Quality Index results (I2 = 91%); subgroup analyses linked it to stimulation frequency and baseline antidepressant use.
Limits & uncertainty
- 1Certainty of evidence was very low to low, and the authors cite methodological limitations in the included trials.
- 2The sleep-quality estimate has a very wide confidence interval (0.23 to 1.71) and I2 of 91%, so the true effect could be small or large.
- 3Only 7 trials were pooled, and subgroup explanations (frequency, antidepressant use) were exploratory. Sleep outcomes depend on questionnaire scores, not objective sleep recordings, as far as the abstract states. This reading is based on the abstract only.
What to take from it
HF-rTMS is a clinic-delivered treatment, and these results are too uncertain to say it works for any individual. It may be a topic to ask about if depression and insomnia persist, but treatment decisions belong with your clinician.
Reading your own data
This is a medical procedure, not something to do or track yourself. If you are in treatment, sleep duration from a wearable and a simple mood log kept on the same device and schedule can show your trend, but they cannot confirm the effect of the treatment.
How to read this evidence
Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
This meta-analysis evaluated the efficacy of high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) targeting the left dorsolateral prefrontal cortex (DLPFC) in patients with comorbid depression and insomnia.
Methods
This analysis incorporated 7 studies, involving 709 subjects (control: 342; repetitive transcranial magnetic stimulation [rTMS]: 367). All included studies employed left DLPFC-targeted HF-rTMS. Treatment effectiveness for comorbid depression and insomnia was assessed. Subgroup analyses were conducted to explore possible sources of heterogeneity.
Results
HF-rTMS significantly improved sleep quality (standardized mean difference [SMD] [95% confidence interval (CI)]: 0.97 [0.23 to 1.71], p = 0.01) and depressive symptoms (0.61 [0.38 to 0.84], p < 0.00001). There was a non-significant trend toward reduced sleep latency (0.50 [-0.17 to 1.18], p = 0.14). No significant difference in adverse reactions was observed (risk ratio [95% CI]: 1.09 [0.80 to 1.48], p = 0.57). Substantial heterogeneity was identified for the Pittsburgh Sleep Quality Index outcomes (I^(2) = 91%). Subgroup analyses indicated that this heterogeneity was attributed to variations in stimulation frequency and baseline antidepressant use.
Conclusion
Very‑low to low certainty evidence suggests that left DLPFC‑targeted HF‑rTMS may improve sleep quality and depressive symptoms in patients with depression and insomnia symptoms, with a favorable safety profile. However, due to substantial heterogeneity and methodological limitations, these findings should be considered exploratory and warrant confirmation by future high‑quality trials.
Sources & attribution
Efficacy of High-Frequency Transcranial Magnetic Stimulation Therapy for Depression With Insomnia Symptoms: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.
Yang W, Chen S, Li X, Chen J, Li L, Yu J.
Brain and behavior · 2026-11-01
DOI: 10.1002/brb3.71808 ↗PubMed · 42947345 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Exercise improved sleep-quality scores in adults 45 and older with sleep disorders
Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.
Journal of Exercise Science & Fitness
Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults
Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.
Sleep
Sleep extension cut daily energy intake by about 270 kcal in adults with overweight
In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.
JAMA Internal Medicine
Six hours or less of sleep at 50 and 60 linked to higher dementia risk
In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.
Nature Communications

